Amgenâ€™s Q3 results show a flat overall revenue with a significant 16% decline in the anemia franchise, primarily due to challenges with ESA sales amid regulatory and reimbursement uncertainties. While other product lines grew and the company implemented cost-saving measures, the negative sentiment around ESA issues and cautious guidance for 2008 are likely to weigh on the stock in the short term.

[-1]